Antibody phage display technologies with special reference to angiogenesis

FASEB Journal

Volumn 19, Issue 3, 2005, Pages 331-341

  Smith, Julia ^a   Kontermann, Roland E ^b   Embleton, Jim ^a,c   Kumar, Shant ^a,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Vectron Therapeutics AG   (Germany)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Angiogenic therapy; CD105; Vascular targeting; Vasculogenesis; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; AUTOANTIBODY; BASIC FIBROBLAST GROWTH FACTOR; CELL MARKER; CILENGITIDE; ENDOGLIN; FIBRONECTIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD105; MONOCLONAL ANTIBODY LM 609; PLATELET DERIVED GROWTH FACTOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BACTERIOPHAGE; CLINICAL TRIAL; CROSS REACTION; DRUG BINDING; DRUG INHIBITION; DRUG TARGETING; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; ISCHEMIC HEART DISEASE; MELANOMA; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RHEUMATOID ARTHRITIS; STROKE; ULCER; UPREGULATION;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; ANTIGENS, CD; ENDOTHELIAL CELLS; FIBRONECTINS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN G; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDE LIBRARY; RECEPTORS, CELL SURFACE; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 14644436317     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.04-2863rev     Document Type: Review

References (107)

1. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31
2. Ballara, S. C., Miotla, J. M., and Paleolog, E. M. (1999) New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders. Int. J. Exp. Pathol. 80, 235-250
3. Duff, S. E., Li, C., Garland, J. M., and Kumar, S. (2003) CD105 is important for angiogenesis: evidence and potential applications. FASEB J. 17, 984-992
4. Hudson, P. J., and Souriau, C. (2003) Engineered antibodies. Nat. Med. 9, 129-134
5. Cao, Y. (2004) Antiangiogenic cancer therapy. Semin. Cancer Biol. 14, 139-145
6. Folkman, J., and Hanahan, D. (1991) Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp. 22, 339-347
7. Lei, Y., Haider, H. K., Shujia, J., and Sim, E. S. (2004) Therapeutic angiogenesis. Devising new strategies based on past experiences. Basic Res. Cardiol. 99, 121-132
8. Steed, D. L. (1995) Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc. Surg. 21, 71-78
9. Hughes, G. C., Biswas, S. S., Yin, B., Coleman, R. E., DeGrado, T. R., Landolfo, C. K., Lowe, J. E., Annex, B. H., and Landolfo, K. P. (2004) Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF. Ann. Thorac. Surg. 77, 812-818
10. Yau, T. M., Li, G., Weisel, R. D., Reheman, A., Jia, Z. Q., Mickle, D. A., and Li, R. K. (2004) Vascular endothelial growth factor transgene expression in cell-transplanted hearts. J. Thorac. Cardiovasc. Surg. 127, 1180-1187
11. Kobayashi, T., Hamano, K., Li, T. S., Katoh, T., Kobayashi, S., Matsuzaki, M., and Esato, K. (2000) Enhancement of angiogenesis by the implantation of self bone marrow cells in a rat ischemic heart model. J. Surg. Res. 89, 189-195
12. Zwaginga, J. J., and Doevendans, P. (2003) Stem cell-derived angiogenic/vasculogenic cells: possible therapies for tissue repair and tissue engineering. Clin. Exp. Pharmacol. Physiol. 30, 900-908
13. Bredow, S., Lewin, M., Hofmann, B., Marecos, E., and Weissleder, R. (2000) Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. Eur. J. Cancer 36, 675-681
14. Huang, S. C., Yu, C. H., Huang, R. T., Hsu, K. F., Tsai, Y. C., and Chou, C. Y. (1996) Intratumoral blood flow in uterine myoma correlated with a lower tumor size and volume, but not correlated with cell proliferation or angiogenesis. Obstet. Gynecol. 87, 1019-1024
15. Molema, G., and Griffioen, A. W. (1998) Rocking the foundations of solid tumor growth by attacking the tumor's blood supply. Immunol. Today 19, 392-394
16. Ran, S., Gao, B., Duffy, S., Watkins, L., Rote, N., and Thorpe, P. E. (1998) Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res. 58, 4646-4653
17. Lode, H. N., Moehler, T., Xiang, R., Jonczyk, A., Gillies, S. D., Cheresh, D. A., and Reisfeld, R. A. (1999) Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc. Natl. Acad. Sci. USA 96, 1591-1596
18. Tucker, G. C. (2003) Alpha v integrin inhibitors and cancer therapy. Curr. Opin. Investig. Drugs 4, 722-731
19. Storgard, C. M., Stupack, D. G., Jonczyk, A., Goodman, S. L., Fox, R. I., and Cheresh, D. A. (1999) Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J. Clin. Invest. 103, 47-54
20. Wei, Y. Q., Wang, Q. R., Zhao, X., Yang, L., Tian, L., Lu, Y., Kang, B., Lu, C. J., Huang, M. J., Lou, Y. Y., et al. (2000) Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat. Med. 6, 1160-1166
21. McDonald, D. M., and Baluk, P. (2002) Significance of blood vessel leakiness in cancer. Cancer Res. 62, 5381-5385
22. Losordo, D. W., Vale, P. R., Symes, J. F., Dunnington, C. H., Esakof, D. D., Maysky, M., Ashare, A. B., Lathi, K., and Isner, J. M. (1998) Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98, 2800-2804
23. Henry, T. D. (1999) Therapeutic angiogenesis. BMJ 318, 1536-1539
24. Isner, J. M., Pieczek, A., Schainfeld, R., Blair, R., Haley, L., Asahara, T., Rosenfield, K., Razvi, S., Walsh, K., and Symes, J. F. (1996) Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348, 370-374
25. Thompson, W. D., Li, W. W., and Maragoudakis, M. (1999) The clinical manipulation of angiogenesis: pathology, side effects, surprises, and opportunities with novel human therapies. J. Pathol. 187, 503-510
26. Simons, M., Bonow, R. O., Chronos, N. A., Cohen, D. J., Giordano, F. J., Hammond, H. K., Laham, R. J., Li, W., Pike, M., Sellke, F. W., et al. (2000) Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. Circulation 102, E73-E86
27. Kohler, G., and Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (London) 256, 495-497
28. Ghetie, V., and Ward, E. S. (1997) FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol. Today 18, 592-598
29. Brekke, O. H., and Loset, G. A. (2003) New technologies in therapeutic antibody development. Curr. Opin. Pharmacol. 3, 544-550
30. Glennie, M. J., and Johnson, P. W. (2000) Clinical trials of antibody therapy. Immunol. Today 21, 403-410
31. Trail, P. A., and Bianchi, A. B. (1999) Monoclonal antibody drug conjugates in the treatment of cancer. Curr. Opin. Immunol. 11, 584-588
32. Matteson, E. L., Yocum, D. E., St Clair, E. W., Achkar, A. A., Thakor, M. S., Jacobs, M. R., Hays, A. E., Heitman, C. K., and Johnston, J. M. (1995) Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum. 38, 1187-1193
33. Adams, G. P., and Schier, R. (1999) Generating improved single-chain Fv molecules for tumor targeting. J. Immunol. Methods 231, 249-260
34. Lee, L. S., Conover, C., Shi, C., Whitlow, M., and Filpula, D. (1999) Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. Bioconjug. Chem. 10, 973-981
35. Zwick, M. B., Shen, J., and Scott, J. K. (1998) Phage-displayed peptide libraries. Curr. Opin. Biotechnol. 9, 427-436
36. Brown, K. C. (2000) New approaches for cell-specific targeting: identification of cell-selective peptides from combinatorial libraries. Curr. Opin. Chem. Biol. 4, 16-21
37. Romanov, V. I. (2003) Phage display selection and evaluation of cancer drug targets. Curr. Cancer Drug Targets 3, 119-129
38. Clackson, T., Hoogenboom, H. R., Griffiths, A. D., and Winter, G. (1991) Making antibody fragments using phage display libraries. Nature (London) 352, 624-628
39. Cai, X., and Garen, A. (1997) Comparison of fusion phage libraries displaying VH or single-chain Fv antibody fragments derived from the antibody repertoire of a vaccinated melanoma patient as a source of melanoma-specific targeting molecules. Proc. Natl. Acad. Sci. USA 94, 9261-9266
40. Hall, B. L., Boroughs, J., and Kobrin, B. J. (1998) A novel tumor-specific human single-chain Fv selected from an active specific immunotherapy phage display library. Immunotechnology 4, 127-140
41. Kupsch, J. M., Tidman, N. H., Kang, N. V., Truman, H., Hamilton, S., Patel, N., Newton Bishop, J. A., Leigh, I. M., and Crowe, J. S. (1999) Isolation of human tumor-specific antibodies by selection of an antibody phage library on melanoma cells. Clin. Cancer Res. 5, 925-931
42. Hoogenboom, H. R., De Bruine, A. P., Hufton, S. E., Hoet, R. M., Arends, J. W., and Roovers, R. C. (1998) Antibody phage display technology and its applications. Immunotechnology 4, 1-20
43. Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., and Winter, G. (1991) By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222, 581-597
44. Winter, G., Griffiths, A. D., Hawkins, R. E., and Hoogenboom, H. R. (1994) Making antibodies by phage display technology. Annu. Rev. Immunol. 12, 433-455
45. Hoogenboom, H. R. (1997) Designing and optimizing library selection strategies for generating high-affinity antibodies. Trends Biotechnol. 15, 62-70
46. Hoogenboom, H. R., Marks, J. D., Griffiths, A. D., and Winter, G. (1992) Building antibodies from their genes. Immunol. Rev. 130, 41-68
47. Garrard, L. J., and Zhukovsky, E. A. (1992) Antibody expression in bacteriophage systems: the future of monoclonal antibodies? Curr. Opin. Biotechnol. 3, 474-480
48. Soderlind, E., Vergeles, M., and Borrebaeck, C. A. (1995) Domain libraries: synthetic diversity for de novo design of antibody V-regions. Gene 160, 269-272
49. Griffiths, A. D., Williams, S. C., Hartley, O., Tomlinson, I. M., Waterhouse, P., Crosby, W. L., Kontermann, R. E., Jones, P. T., Low, N. M., and Allison, T. J. (1994) Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13, 3245-3260
50. Knappik, A., Ge, L., Honegger, A., Pack, P., Fischer, M., Wellnhofer, G., Hoess, A., Wolle, J., Pluckthun, A., and Virnekas, B. (2000) Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol. 296, 57-86
51. Volkel, T., Muller, R., and Kontermann, R. E. (2004) Isolation of endothelial cell-specific human antibodies from a novel fully synthetic scFv library. Biochem. Biophys. Res. Commun. 317, 515-521
52. Holt, L. J., Bussow, K., Walter, G., and Tomlinson, I. M. (2000) By-passing selection: direct screening for antibody-antigen interactions using protein arrays. Nucleic Acids Res. 28, E72
53. Siegel, D. L. (2002) Recombinant monoclonal antibody technology. Transfus. Clin. Biol. 9, 15-22
54. Vaughan, T. J., Williams, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R., Earnshaw, J. C., McCafferty, J., Hodits, R. A., Wilton, J., and Johnson, K. S. (1996) Human antibodies with subnanomolar affinities isolated from a large nonimmunized phage display library. Nat. Biotechnol. 14, 309-314
55. Sheets, M. D., Amersdorfer, P., Finnern, R., Sargent, P., Lindquist, E., Schier, R., Hemingsen, G., Wong, C., Gerhart, J. C., Marks, J. D., et al. (1998) Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc. Natl. Acad. Sci. USA 95, 6157-6162
56. Soderlind, E., Ohlin, M., and Carlsson, R. (1999) Complementarity- determining region (CDR) implantation: a theme of recombination. Immunotechnology 4, 279-285
57. Carlsson, R., and Soderlind, E. (2001) n-CoDeR concept: unique types of antibodies for diagnostic use and therapy. Expert Rev. Mol. Diagn. 1, 102-108
58. Jung, S., Honegger, A., and Pluckthun, A. (1999) Selection for improved protein stability by phage display. J. Mol. Biol. 294, 163-180
59. Cai, X., and Garen, A. (1995) Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries. Proc. Natl. Acad. Sci. USA 92, 6537-6541
60. Giordano, R. J., Cardo-Vila, M., Lahdenranta J., Pasqualini, R., and Arap, W. (2001) Biopanning and rapid analysis of selective interactive ligands. Nat. Med. 7, 1249-1253
61. Viti, F., Giovannoni, L., and Neri, D. (2002) Recombinant antibodies for the selective targeting of tumor neovasculature. Curr. Opin. Drug Discov. Dev. 5, 204-213
62. Arap, W., Kolonin, M. G., Trepel, M., Lahdenranta, J., Cardo-Vila, M., Giordano, R. J., Mintz, P. J., Ardelt, P. U., Yao, V. J., Vidal, C. I., et al. (2002) Steps toward mapping the human vasculature by phage display. Nat. Med. 8, 121-127
63. Lekkerkerker, A., and Logtenberg, T. (1999) Phage antibodies against human dendritic cell subpopulations obtained by flow cytometry-based selection on freshly isolated cells. J. Immunol. Methods 231, 53-63
64. Rajotte, D., Arap, W., Hagedorn, M., Koivunen, E., Pasqualini, R., and Ruoslahti, E. (1998) Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J. Clin. Invest. 102, 430-437
65. Maruta, F., Parker, A. L., Fisher, K. D., Murray, P. G., Kerr, D. J., and Seymour, L. W. (2003) Use of a phage display library to identify oligopeptides binding to the lumenal surface of polarized endothelium by ex vivo perfusion of human umbilical veins. J. Drug Target. 11, 53-59
66. Griffiths, A. D., Malmqvist, M., Marks, J. D., Bye, J. M., Embleton, M. J., McCafferty, J., Baier, M., Holliger, K. P., Gorick, B. D., and Hughes-Jones, N. C. (1993) Human anti-self antibodies with high specificity from phage display libraries. EMBO J. 12, 725-734
67. Ruan, B., Hoskins, J., Wang, L., and Bryan, P. N. (1998) Stabilizing the subtilisin BPN' pro-domain by phage display selection: how restrictive is the amino acid code for maximum protein stability? Protein Sci. 7, 2345-2353
68. Sieber, V., Pluckthun, A., and Schmid, F. X. (1998) Selecting proteins with improved stability by a phage-based method. Nat. Biotechnol. 16, 955-960
69. Adams, G. P. (1998) Improving the tumor specificity and retention of antibody-based molecules. In Vivo 12, 11-21
70. Schier, R., McCall, A., Adams, G. P., Marshall, K. W., Merritt, H., Yim, M., Crawford, R. S., Weiner, L. M., Marks, C., and Marks, J. D. (1996) Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol. 263, 551-567
71. Lu, D., Shen, J., Vil, M. D., Zhang, H., Jimenez, X., Bohlen, P., Witte, L., and Zhu, Z. (2003) Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J. Biol. Chem. 278, 43496-43507
72. Atwell, J. L., Breheney, K. A., Lawrence, L. J., McCoy, A. J., Kortt, A. A., and Hudson, P. J. (1999) scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. Protein Eng. 12, 597-604
73. Persaud, K., Tille, J. C., Liu, M., Zhu, Z., Jimenez, X., Pereira, D. S., Miao, H. Q., Brennan, L. A., Witte, L., Pepper, M. S., et al. (2004) Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C. J. Cell Sci. 117, 2745-2756
74. Nettelbeck, D. M., Miller, D. W., Jerome, V., Zuzarte, M., Watkins, S. J., Hawkins, R. E., Muller, R., and Kontermann, R. E. (2001) Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol. Ther. 3, 882-891
75. Vitaliti, A., Wittmer, M., Steiner, R., Wyder, L., Neri, D., and Klemenz, R. (2000) Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor. Cancer Res. 60, 4311-4314
76. Cooke, S. P., Boxer, G. M., Lawrence, L., Pedley, R. B., Spencer, D. I., Begent, R. H., and Chester, K. A. (2001) A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex. Cancer Res. 61, 3653-3659
77. Cai, M., Zhang, H., and Hui, R. (2003) Single chain Fv antibody against angiopoietin-2 inhibits VEGF-induced endothelial cell proliferation and migration in vitro. Biochem. Biophys. Res. Commun. 309, 946-951
78. Brocks, B., Garin-Chesa, P., Behrle, E., Park, J. E., Rettig, W. J., Pfizenmaier, K., and Moosmayer, D. (2001) Species-crossreactive scFv against the tumor stroma marker "fibroblast activation protein" selected by phage display from an immunized FAP-/- knock-out mouse. Mol. Med. 7, 461-469
79. Rippmann, J. F., Pfizenmaier, K., Mattes, R., Rettig, W. J., and Moosmayer, D. (2000) Fusion of the tissue factor extracellular domain to a tumour stroma specific single-chain fragment variable antibody results in an antigen-specific coagulation-promoting molecule. Biochem. J. 349, 805-812
80. Carnemolla, B., Castellani, P., Ponassi, M., Borsi, L., Urbini, S., Nicolo, G., Dorcaratto, A., Viale, G., Winter, G., Neri, D., et al. (1999) Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am. J. Pathol. 154, 1345-1352
81. Viti, F., Tarli, L., Giovannoni, L., Zardi, L., and Neri, D. (1999) Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res. 59, 347-352
82. Sanz, L., Kristensen, P., Blanco, B., Facteau, S., Russell, S. J., Winter, G., and Alvarez-Vallina, L. (2002) Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther. 9, 1049-1053
83. Mutuberria, R., Hoogenboom, H. R., van der, L. E., De Bruine, A. P., and Roovers, R. C. (1999) Model systems to study the parameters determining the success of phage antibody selections on complex antigens. J. Immunol. Methods 231, 65-81
84. Hannum, R. S., Ojeifo, J. O., Zwiebel, J. A., and McLeskey, S. W. (2001) Isolation of tumor-derived endothelial cells. Microvasc. Res. 61, 287-290
85. Essler, M., and Ruoslahti, E. (2002) Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc. Natl. Acad. Sci. USA 99, 2252-2257
86. Costello, B., Li, C., Duff, S., Butterworth, D., Khan, A., Perkins, M., Owens, S., Al Mowallad, A. F., O'Dwyer, S., and Kumar, S. (2004) Perfusion of 99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target. Int. J. Cancer 109, 436-441
87. Hood, J. D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R. A., Xiang, R., and Cheresh, D. A. (2002) Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404-2407
88. Hu, J., Van den Steen, P. E., Houde, M., Ilenchuk, T. T., and Opdenakker, G. (2004) Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody. Biochem. Pharmacol. 67, 1001-1009
89. Ferrara, N. (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 29, 10-14
90. Li, L., Wartchow, C. A., Danthi, S. N., Shen, Z., Dechene, N., Pease, J., Choi, H. S., Doede, T., Chu, P., Ning, S., et al. (2004) A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int. J. Radiat. Oncol. Biol. Phys. 58, 1215-1227
91. Gutheil, J. C., Campbell, T. N., Pierce, P. R., Watkins, J. D., Huse, W. D., Bodkin, D. J., and Cheresh, D. A. (2000) Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin. Cancer Res. 6, 3056-3061
92. Wilder, R. L. (2002) Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann. Rheum. Dis. 61, Suppl 2, ii96-ii99
93. Brekken, R. A., Li, C., and Kumar, S. (2002) Strategies for vascular targeting in tumors. Int. J. Cancer 100, 123-130
94. Balza, E., Castellani, P., Zijlstra, A., Neri, D., Zardi, L., and Siri, A. (2001) Lack of specificity of endoglin expression for tumor blood vessels. Int. J. Cancer 94, 579-585
95. Korn, T., Muller, R., and Kontermann, R. E. (2004) Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes. J. Immunother. 27, 99-106
96. Volkel, T., Holig, P., Merdan, T., Muller, R., and Kontermann, R. E. (2004) Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim. Biophys. Acta 1663, 158-166
97. Demartis, S., Tarli, L., Borsi, L., Zardi, L., and Neri, D. (2001) Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur. J. Nucleic Med. 28, 534-539
98. Birchler, M., Viti, F., Zardi, L., Spiess, B., and Neri, D. (1999) Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nat. Biotechnol. 17, 984-988
99. Halin, C., Rondini, S., Nilsson, F., Berndt, A., Kosmehl, H., Zardi, L., and Neri, D. (2002) Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat. Biotechnol. 20, 264-269
100. Carnemolla, B., Borsi, L., Balza, E., Castellani, P., Meazza, R., Berndt, A., Ferrini, S., Kosmehl, H., Neri, D., and Zardi, L. (2002) Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99, 1659-1665
101. Nilsson, F., Kosmehl, H., Zardi, L., and Neri, D. (2001) Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res. 61, 711-716
102. Marty, C., Odermatt, B., Schott, H., Neri, D., Ballmer-Hofer, K., Klemenz, R., and Schwendener, R. A. (2002) Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br. J. Cancer 87, 106-112
103. Borsi, L., Balza, E., Carnemolla, B., Sassi, F., Castellani, P., Berndt, A., Kosmehl, H., Biro, A., Siri, A., Orecchia, P., et al. (2003) Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 102, 4384-4392
104. Wuest, T., Moosmayer, D., and Pfizenmaier, K. (2001) Construction of a bispecific single chain antibody for recruitment of cytotoxic T cells to the tumour stroma associated antigen fibroblast activation protein. J. Biotechnol. 92, 159-168
105. Hoogenboom, H. R., Henderikx, P., and de Haard, H. (1998) Creating and engineering human antibodies for immunotherapy. Adv. Drug Deliv. Rev. 31, 5-31
106. Hoogenboom, H. R. (2002) Overview of antibody phage-display technology and its applications. Methods Mol. Biol. 178, 1-37
107. Azzazy, H. M., and Highsmith, W. E., Jr. (2002) Phage display technology: clinical applications and recent innovations. Clin. Biochem. 35, 425-445